The 25-Year Cumulative Incidence of Lower Extremity Amputations in People With Type 1 Diabetes

KARINE SAHAKYAN, MD, MPH
BARBARA E.K. KLEIN, MD, MPH
KRISTINE E. LEE, MS

CHELSEA E. MYERS, MSTAT
RONALD KLEIN, MD, MPH

OBJECTIVE—To examine the 25-year cumulative incidence of lower-extremity amputation (LEA) in people with type 1 diabetes.

RESEARCH DESIGN AND METHODS—Cumulative incidence of LEA was ascertained in Wisconsin Epidemiologic Study of Diabetic Retinopathy participants (n = 943) using the Kaplan-Meier approach accounting for competing risk of death. Relationships of baseline characteristics with incidence of LEA were explored using a proportional hazards approach with discrete linear regression modeling.

RESULTS—The overall 25-year incidence of LEA was 10.1%. In multivariate analyses (results reported as odds ratio; 95% CI), being male (3.90; 2.29–6.65), heavy smoking (2.07; 1.11–3.85), having hypertension (3.36; 1.91–5.93), diabetic retinopathy (2.62; 1.13–6.09), neuropathy (1.68; 1.02–2.76), and higher HbA1c (per 1% 1.40; 1.24–1.58) were independently associated with the incidence of LEA.

CONCLUSIONS—Our results show a high 25-year incidence of LEA and suggest that glycemic control and blood pressure control and preventing heavy smoking may result in reduction in its incidence.

Several studies have described the incidence of lower-extremity amputation (LEA) and its relationship to various risk factors such as glycemia and blood pressure (1–5), but few have studied cohorts of people with type 1 diabetes followed over a long period (1–4). Despite changes in care, the incidence of LEA remains high, at 0.15–0.36% per 10,000 people (2,3,5). In this study, we examine the 25-year cumulative incidence of LEA in a large cohort with type 1 diabetes participating in the Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR).

RESULTS—Eighty-seven people had incident LEA. Of these, 53 (60.9%) had a toe or foot amputated, 13 (14.9%) had a leg amputated, and 21 (24.1%) had an amputation of a toe or foot followed by a leg. The 25-year overall cumulative incidence of LEA accounting for competing risk of death was 10.1% (95% CI 8.1–12.1); the 25-year cumulative incidence of major LEA (leg amputations) was 4.2% (95% CI 2.8–5.6). Cumulative incidence of LEA was related to baseline age (P < 0.001 for trend) and duration of diabetes (P = 0.02 for trend).

Male sex and other characteristics were univariately associated with the incidence of LEA (Table 1). In multivariate analyses (OR; 95% CI), male sex (3.90; 2.29–6.65), heavy smoking (2.07; 1.11–3.85), hypertension (3.36; 1.91–5.93), diabetic retinopathy (2.62; 1.13–6.09), history of peripheral neuropathy (1.68;
The 25-year incidence of LEA

Table 1—Associations with incidence of LEA

|                        | Univariate |          | Multivariate |          |
|------------------------|------------|----------|--------------|----------|
|                        | OR  | 95% CI   | P value      | OR  | 95% CI   | P value      |
| Sex (male vs. female)  | 3.25 | 1.99–5.28 | <0.001       | 3.90 | 2.29–6.65 | <0.001       |
| Age at diagnosis (years) |     |          |              |        |          |              |
| 10–19 vs. <10          | 0.71 | 0.41–1.22 | 0.21         | 0.72 | 0.41–1.28 | 0.21         |
| 20–29 vs. <10          | 0.52 | 0.27–0.99 | 0.07         | 0.52 | 0.27–0.99 | 0.07         |
| Glycosylated hemoglobin A1c (per 1%) | 1.36 | 1.22–1.52 | <0.001       | 1.40 | 1.24–1.58 | <0.001       |
| Glycosylated hemoglobin A1c quartiles (%) | |          |              |        |          |              |
| 9.5–10.5 vs. <9.5     | 1.63 | 0.88–3.03 | 0.12         | 1.63 | 0.88–3.03 | 0.12         |
| 10.6–12.0 vs. <9.5    | 1.99 | 1.09–3.64 | 0.03         | 1.99 | 1.09–3.64 | 0.03         |
| 12.1–19.5 vs. <9.5    | 4.61 | 2.49–8.54 | <0.001       | 4.61 | 2.49–8.54 | <0.001       |
| Diabetic retinopathy  | 3.83 | 1.71–8.58 | 0.001        | 2.62 | 1.13–6.09 | 0.04         |
| Diabetic retinopathy severity | |          |              |        |          |              |
| Mild vs. none          | 1.91 | 0.79–4.61 | 0.15         | 1.91 | 0.79–4.61 | 0.15         |
| Moderate vs. none      | 3.99 | 1.49–10.67| 0.006        | 3.99 | 1.49–10.67| 0.006        |
| PDR vs. none           | 13.53| 5.73–31.93| <0.001       | 13.53| 5.73–31.93| <0.001       |
| Proteinuria            | 2.85 | 1.77–4.59 | <0.001       | 1.34 | 0.74–2.41 | 0.34         |
| Hypertension           | 3.21 | 2.03–5.06 | <0.001       | 3.60 | 1.91–5.93 | <0.001       |
| Smoking history        |      |          |              |        |          |              |
| Past vs. never         | 1.77 | 0.98–3.20 | 0.06         | 1.77 | 0.98–3.20 | 0.06         |
| Current vs. never      | 2.01 | 1.23–3.90 | 0.006        | 2.01 | 1.23–3.90 | 0.006        |
| Pack years smoked      |      |          |              |        |          |              |
| <5 vs. none            | 1.44 | 0.73–2.84 | 0.30         | 1.26 | 0.58–2.72 | 0.56         |
| 5–14 vs. none          | 1.90 | 0.99–3.64 | 0.05         | 1.28 | 0.63–2.60 | 0.50         |
| ≥15 vs. none           | 2.52 | 1.43–4.46 | 0.01         | 2.07 | 1.11–3.85 | 0.02         |
| Cardiovascular disease history* | 0.95 | 0.27–3.17 | 0.91         | 0.95 | 0.27–3.17 | 0.91         |
| Neuropathy history     | 2.00 | 1.27–3.16 | 0.003        | 1.68 | 1.02–2.76 | 0.04         |
| BMI (kg/m²)            |      |          |              |        |          |              |
| 25–30 vs. <25          | 1.13 | 0.70–1.83 | 0.61         | 1.13 | 0.70–1.83 | 0.61         |
| >30 vs. <25            | 0.45 | 0.14–1.46 | 0.18         | 0.45 | 0.14–1.46 | 0.18         |

All models (univariate and multivariate) additionally control for age. Missing rows indicate that variable was not sign
ificant and thus not included in the final multivariate model. Smoking history was not entered in the model because of multicollinearity with pack years smoked variable. PDR, proliferative diabetic retinopathy.

*Defined as having a history of angina, myocardial infarction, or stroke.

1.02–2.76), and higher HbA1c level (per 1% 1.40; 1.24–1.58) were independently associated with 25-year incidence of LEA. Additionally, we performed time-dependent covariate analyses using data on all baseline variables at each follow-up visit. Our results showed that time-varying covariate associations of risk factors with LEA were consistent with association of baseline risk factors and LEA incidence.

CONCLUSIONS—The overall 25-year cumulative incidence of LEA, 10.1%, was high. Male sex, history of heavy smoking, higher HbA1c, presence of hypertension, presence of retinopathy, and history of diabetic neuropathy were associated with LEA after controlling for age.

Our data confirm previous findings of a higher incidence of LEA in men (4,8), possibly related to higher prevalence of smoking in men. However, the association remained after controlling for smoking status (8). The lower incidence of LEA in women may be partially because of lower incidence of peripheral vascular disease in women (9). The lower occurrence of foot ulcers in women suggests that poorer self-care in men may also contribute to the finding of higher incidence of LEA in men (10).

Heavy smoking was related to incidence of LEA, which may be explained by the association of current and heavy smoking with development of atherosclerosis and peripheral arterial disease (9,11).

In the WESDR, people with hypertension and higher HbA1c had increased risk of LEA. Similarly, in the United Kingdom Prospective Diabetes Study, duration and degree of hyperglycemia and increased systolic blood pressure were associated with increased risk of peripheral arterial disease, independently of other factors (12).

Other studies have found a relationship of retinopathy to LEA (13), suggesting that microvascular disease may be involved in the pathogenesis of LEA. History of neuropathy at baseline was independently associated with 62% increased odds of incident LEA. This may be because of decreased pain perception, impaired circulation and sensation, and, consequently, foot ulceration and infection in people with type 1 diabetes and neuropathy (9,14,15).

Longer diabetes duration, hyperglycemia, hyperlipidemia, and retinopathy have shown associations with LEA in people with type 2 diabetes (13). We previously compared 10-year cumulative incidence of LEA and associated risk factors in people with type 1 and 2 diabetes in our cohort. We found that while adjusting for diabetes duration, 10-year incidence of LEA was lower in people with type 1 diabetes than in people with type 2 diabetes. Differences in glycemic control did not explain this. It may be partially a result of poorer blood pressure control, higher frequency of atherosclerosis, and other factors not measured in our study in people with type 2 diabetes.

Our study has many strengths and some limitations. Despite the large proportion, the absolute number of LEAs was relatively small, reducing power to find some associations. Poorer survival in people with both histories of cardiovascular disease and LEA compared with those with cardiovascular disease without LEA suggests that selective mortality may have diminished the estimate of the effects of risk factors such as smoking or hypertension (K.S., unpublished data). Additionally, potential confounders, e.g., history of peripheral vascular disease and serum lipid levels, were not evaluated at baseline.

We found a high 25-year cumulative incidence of LEA in people with type 1 diabetes associated with three modifiable risk factors: hyperglycemia, hypertension, and heavy smoking. Glycemic and blood pressure control and preventing heavy smoking may result in its reduced incidence.

Acknowledgments—This work was supported by National Institutes of Health (Bethesda, MD)
Grants EY-016379 (to B.E.K.K. and R.K.) and DK-073217 (to R.K.) and by the American Diabetes Association (Alexandria, VA) Mentor-Based Postdoctoral Fellowship Award (to R.K.).

No potential conflicts of interest relevant to this article were reported.

K.S. researched data, contributed to discussion, wrote the article, and reviewed and edited the article. B.E.K.K. researched data, contributed to discussion, and reviewed and edited the article. K.E.L. and C.E.M. contributed to discussion and reviewed and edited the article. R.K. researched data, contributed to discussion, and reviewed and edited the article.

Parts of this study were presented in abstract form at the 70th Scientific Sessions of the American Diabetes Association, Orlando, Florida, 25–29 June 2010.

References

1. Humphrey AR, Dowse GK, Thoma K, Zimmet PZ. Diabetes and nontraumatic lower extremity amputations. Incidence, risk factors, and prevention—a 12-year follow-up study in Nauru. Diabetes Care 1996;19:710–714
2. Canavan RJ, Unwin NC, Kelly WF, Connolly VM. Diabetes- and nondiabetes-related lower extremity amputation incidence before and after the introduction of better organized diabetes foot care: continuous longitudinal monitoring using a standard method. Diabetes Care 2008;31:459–463
3. van Houtum WH, Rauwerda JA, Ruwaard D, Schaper NC, Bakker K. Reduction in diabetes-related lower-extremity amputations in The Netherlands: 1991-2000. Diabetes Care 2004;27:1042–1046
4. Calle-Pascual AL, Garcia-Torre N, Moraga I, et al. Epidemiology of nontraumatic lower-extremity amputation in area 7, Madrid, between 1989 and 1999: a population-based study. Diabetes Care 2003;26:1686–1689
5. Schofield CJ, Yu N, Jain AS, Leese GP. Decreasing amputation rates in patients with diabetes—a population-based study. Diabet Med 2009;26:773–777
6. Klein R, Knudson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII; the twenty-five-year progression of retinopathy in persons with type 1 diabetes. Ophthalmology 2008;115:1859–1868
7. Moss SE, Klein R, Klein BE, Spennetta TL, Shrago ES. Methodologic considerations in measuring glycosylated hemoglobin in epidemiologic studies. J Clin Epidemiol 1988;41:643–649
8. Jonsson JM, Ye W, Sparén P, Apeleqvist J, Nyrén O, Brismar K. Risks of nontraumatic lower-extremity amputations in patients with type 1 diabetes: a population-based cohort study in Sweden. Diabetes Care 2008;31:1536–1540
9. Jude EB, Eleftheriadou I, Tentolouris N. Peripheral arterial disease in diabetes—a review. Diabet Med 2010;27:4–14
10. Hokkam EN. Assessment of risk factors in diabetic foot ulceration and their impact on the outcome of the disease. Prim Care Diabetes 2009;3:219–224
11. Marso SP, Hiatt WR. Peripheral arterial disease in patients with diabetes. J Am Coll Cardiol 2006;47:921–929
12. Adler AI, Stevens RJ, Neil A, Stratton IM, Boulton AJ, Holman RR. UKPDS 59: hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes. Diabetes Care 2002;25:894–899
13. Chaturvedi N, Stevens LK, Fuller JH, Lee ET, Lu M. The WHO Multinational Study of Vascular Disease in Diabetes. Risk factors, ethnic differences and mortality associated with lower-extremity gangrene and amputation in diabetes. Diabetologia 2001;44(Suppl. 2):S65–S71
14. Pecoraro RE, Ahroni JH, Boyko EJ, Stensel VL. Chronology and determinants of tissue repair in diabetic lower-extremity ulcers. Diabetes 1991;40:1305–1313
15. Reiber GE, Vileikyte L, Boyko EJ, et al. Causal pathways for incident lower-extremity ulcers in patients with diabetes from two settings. Diabetes Care 1999;22:157–162